Found 6 matching trials
Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study PHASE1 Colorectal cancer (CRC) is the fourth leading cause of cancer death worldwi...
Show More Status
Active Not Recruiting
Location
Tianjin Cancer Hospital
Learn More & Join Trial
A Study of XZB-0004 in Patients With Solid Tumors PHASE1 XZB-0004 is a novel and potent small molecule inhibitor of receptor tyrosin...
Show More Location
Shanghai Pulmonary Hospital
Learn More & Join Trial
Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma N/A Hepatic artery infusion chemotherapy (HAIC) has shown promising outcomes in...
Show More Location
Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center,
Learn More & Join Trial
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma NA This study is a prospective, multicenter, open, real-world clinical study. ...
Show More Location
Multiple Locations
Learn More & Join Trial
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites PHASE1 This study is to evaluate the safety and efficacy of intraperitoneal inject...
Show More Location
Qilu Hospital of Shandong University
Learn More & Join Trial
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer NA This is a single-center, open label, single-arm, investigator-initiated stu...
Show More Location
Peking Union Medical College Hospital
Learn More & Join Trial